MagGenix

MagGenix is a biotechnology company based in Baltimore, Maryland, that is developing a patent-pending magnetogenetic platform designed to control cellular activity using electromagnetic waves. By applying this technology, the company aims to enable precise cellular activation in terms of both location and timing, which can be applied across clinical, industrial, and research environments. Their approach allows for the use of non-invasive electromagnetic stimulation to modulate engineered cells, offering a potential advancement over existing optogenetic or chemogenetic methods for perturbing biological systems.

The platform is designed to improve the delivery and management of cell-based therapies, such as CAR-T cells, by allowing them to function specifically at targeted sites like tumors or inflamed joints, thereby minimizing off-target effects and systemic immune disruption. Additionally, the technology is intended for use in bioproduction, where it can provide cost-efficient control over cellular synthesis within large-scale bioreactors. By connecting the electronic and biological domains, MagGenix seeks to offer a versatile toolset that can be implemented in various therapeutic and manufacturing processes.